CD8A and HIV infectious disease: Notably, these studies highlight a potential vaccinal effect of bNAb therapy on CD8+ T cell activity by activating antigen-presenting cells through the formation of antibody:HIV-1-antigen immune complex, underscoring the benefits of bNAb administration in the first weeks after diagnosis when the immune response may not yet be compromised by HIV infection [187].